Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. (United States) holds 0 active US FDA Type II Drug Master Files and 1 inactive and is linked to 1 FDA-registered manufacturing site. 1 FDA enforcement record is linked to it.
Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records
Cite as: PharmaTek, “Sarepta Therapeutics, Inc.: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/sarepta-therapeutics-inc
Overview
Sarepta Therapeutics, Inc. is a medical research and drug development company focused on developing precision genetic medicines to treat rare neuromuscular diseases. With a primary emphasis on Duchenne muscular dystrophy, the company utilizes innovative RNA-based platforms to address unmet medical needs.
Therapeutic areas
API / Drug Master Files
Sarepta Therapeutics, Inc. holds 0 active (1 total) FDA Type II Drug Master File. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.
- SRP-2001 DRUG SUBSTANCEInactive2023-02-28
Registered manufacturing sites (1)
Physical sites registered with the US FDA and resolved to Sarepta Therapeutics, Inc., with any EU/UK GMP documents matched to each site. Headquarters and manufacturing locations can differ.
FDA compliance signals
1 FDA enforcement record linked to this company.
- 4832018-04-12
Periodic safety report missing ICSR
Is this Sarepta Therapeutics, Inc.?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.
Need suppliers found and checked?
The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.